- Home
- » Tags
- » Cilansetron
Top View
- Meta-Analysis: Factors Affecting Placebo Response Rate in Irritable Bowel Syndrome. Alexander Ford, Paul Moayyedi
- Meta-Analysis: the Treatment of Irritable Bowel Syndrome
- Prokinetics in the Management of Functional Gastrointestinal Disorders
- Long-Term Efficacy and Safety of Ramosetron in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
- Lubiprostone: Evaluation of the Newest Medication for the Treatment of Adult Women with Constipation-Predominant Irritable Bowel Syndrome
- Drug Treatment of Irritable Bowel Syndrome: Different Approaches for Different Subtypes
- Neuronal 5-HT Receptors and SERT
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- Brain-Gut Interactions in IBS
- Efficacy and Safety of 5-Hydroxytryptamine 3 Receptor Antagonists in Irritable Bowel Syndrome: a Systematic Review and Meta- Analysis of Randomized Controlled Trials
- Randomized, Double Blinded, Placebo Controlled Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients with Bile Acid Malabsorption
- Tepzz¥ 4¥5 4A T
- (12) United States Patent (10) Patent No.: US 9.248,185 B2 Rubin Et Al
- Serotonin and Its Role in Colonic Function and in Gastrointestinal Disorders Meagan M
- How Serotonin Level Fluctuation Affects the Effectiveness of Treatment in Irritable Bowel Syndrome
- Customs Tariff - Schedule Xxi - 1
- IBS-Monograph-2018.Pdf
- Pharmacology of Serotonin: What a Clinician Should Know
- Human Neurogenesis Assay: Ramelteon
- (12) United States Patent (10) Patent No.: US 6,566,369 B2 Cautreels Et Al
- Serotonin Receptor Modulators in the Treatment of Irritable Bowel Syndrome
- (19) United States (12) Patent Application Publication (10) Pub
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- (12) United States Patent (10) Patent No.: US 8,791,093 B2 G00 Berman (45) Date of Patent: Jul
- Serotonergic Modulation of Visceral Sensation: Lower Gut M Camilleri
- Comprehensive Pgx Report for John Doe
- Neurotransmitter Dysfunction in Irritable Bowel Syndrome: Emerging Approaches for Management
- Irritable Bowel Syndrome
- New Therapeutic Approaches in Irritable Bowel Syndrome
- Comparative Effectiveness of 5-Hydroxytryptamine 3 Receptor Antagonists in Irritable Bowel Syndrome: a Network Meta-Analysis of Randomized Controlled Studies
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation
- Doug Drossman CV
- Gastroprokinetic Agent, Mosapride Inhibits 5-HT3 Receptor Currents in NCB-20 Cells Yong Soo Park1 and Ki-Wug Sung2,*
- Cilansetron: a Novel, High-Affinity 5-HT Receptor Antagonist For
- 5-HT3 Receptor Antagonists for the Treatment of Nausea/Vomiting
- Irritable Bowel Syndrome)
- Disorders of Gastrointestinal Hypomotility[Version 1; Peer Review
- Sample Report US Version Report Number: PGX-AGS00000 Report Date
- CSTI-300 (SMP-100); a Novel 5-HT3 Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome Or Carcinoid Syndrome S
- 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: the Iceberg Still Lies Beneath the Surface